84 related articles for article (PubMed ID: 2906631)
1. Neurons from substantia nigra increase the efficacy and potency of second messenger arising from striatal astroglia dopamine receptor.
Hansson E; Rönnbäck L
Glia; 1988; 1(6):393-7. PubMed ID: 2906631
[TBL] [Abstract][Full Text] [Related]
2. Explant cultures of dog substantia nigra and striatum: a model for the study of nigro-striatal dopamine neurons.
Mytilineou C; Cohen G; Dembiec-Cohen D; Van Woert M; Hwang E
J Neural Transm Suppl; 1983; 19():37-51. PubMed ID: 6321649
[TBL] [Abstract][Full Text] [Related]
3. D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.
Weiss S; Sebben M; Garcia-Sainz JA; Bockaert J
Mol Pharmacol; 1985 Jun; 27(6):595-9. PubMed ID: 2987658
[TBL] [Abstract][Full Text] [Related]
4. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
[TBL] [Abstract][Full Text] [Related]
5. Neuronal links in the CNS: focus on dopaminergic and serotonergic regulation of striatal cholinergic neurons.
Garattini S; Consolo S; Ladinski H
Pol J Pharmacol Pharm; 1980; 32(2):155-64. PubMed ID: 7454621
[TBL] [Abstract][Full Text] [Related]
6. Effects of NMDA and MK-801 injected into the substantia nigra pars reticulata on jaw movements evoked by dopamine D1-/D2 receptor stimulation in the ventrolateral striatum: studies in freely moving rats.
Uchida T; Lee J; Fujita S; Kiguchi M; Matsumoto M; Oi Y; Gionhaku N; Koshikawa N
Methods Find Exp Clin Pharmacol; 2005; 27(1):31-7. PubMed ID: 15834457
[TBL] [Abstract][Full Text] [Related]
7. Survival and differentiation of dopaminergic mesencephalic neurons are promoted by dopamine-mediated induction of FGF-2 in striatal astroglial cells.
Reuss B; Unsicker K
Mol Cell Neurosci; 2000 Dec; 16(6):781-92. PubMed ID: 11124897
[TBL] [Abstract][Full Text] [Related]
8. Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.
Marti M; Manzalini M; Fantin M; Bianchi C; Della Corte L; Morari M
J Neurochem; 2005 Apr; 93(1):195-205. PubMed ID: 15773919
[TBL] [Abstract][Full Text] [Related]
9. Intermittent morphine administration induces a long-lasting synergistic effect of corticosterone on dopamine D1 receptor functioning in rat striatal GABA neurons.
Schoffelmeer AN; De Vries TJ; Vanderschuren LJ; Tjon GH; Nestby P; Wardeh G; Mulder AH
Synapse; 1997 Apr; 25(4):381-8. PubMed ID: 9097397
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons.
Kitai ST; Surmeier DJ
Adv Neurol; 1993; 60():40-52. PubMed ID: 8380527
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system.
Karakaya S; Kipp M; Beyer C
J Neuroendocrinol; 2007 Sep; 19(9):682-90. PubMed ID: 17680883
[TBL] [Abstract][Full Text] [Related]
12. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
Zeevalk GD; Manzino L; Sonsalla PK
Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
[TBL] [Abstract][Full Text] [Related]
13. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
Carlson JH; Bergstrom DA; Weick BG; Walters JR
Synapse; 1987; 1(5):411-6. PubMed ID: 2975067
[TBL] [Abstract][Full Text] [Related]
15. Role of striato-nigral substance P in the regulation of the activity of the nigro-striatal dopaminergic neurons.
Glowinski J; Michelot R; Chéramy A
Adv Biochem Psychopharmacol; 1980; 22():51-62. PubMed ID: 6156583
[No Abstract] [Full Text] [Related]
16. Differential perikaryal localization in rats of D1 and D2 dopamine receptors on striatal projection neuron types identified by retrograde labeling.
Deng YP; Lei WL; Reiner A
J Chem Neuroanat; 2006 Dec; 32(2-4):101-16. PubMed ID: 16914290
[TBL] [Abstract][Full Text] [Related]
17. BDNF-dependent stimulation of dopamine D5 receptor expression in developing striatal astrocytes involves PI3-kinase signaling.
Brito V; Beyer C; Küppers E
Glia; 2004 May; 46(3):284-95. PubMed ID: 15048851
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular dopamine receptors: recent advances in agonists and antagonists of the DA1-receptor.
Berkowitz BA; Ohlstein EH
J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S559-63. PubMed ID: 6210423
[TBL] [Abstract][Full Text] [Related]
19. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
20. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
Kelland MD; Freeman AS; Chiodo LA
Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
